|
|
Volumn 29, Issue 11, 2011, Pages 960-
|
|
Hemophilia market awaits next-generation therapies.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BLOOD CLOTTING FACTOR;
BLOOD CLOTTING FACTOR 8;
RECOMBINANT PROTEIN;
ECONOMICS;
HEALTH CARE COST;
HEMOPHILIA A;
HUMAN;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
BLOOD COAGULATION FACTORS;
CLINICAL TRIALS, PHASE III AS TOPIC;
FACTOR VIII;
HEALTH CARE SECTOR;
HEMOPHILIA A;
HUMANS;
RECOMBINANT PROTEINS;
|
|
EID: 84857705164
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1111-960c Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
